文献速递神经肿瘤

成人丘脑胶质瘤:临床特征、治疗策略与生存结局的系统综述

Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes.
PubMed 文献 · J Neurooncol · 2021-11-19

该系统综述纳入25项研究共617例成人丘脑胶质瘤患者,中位年龄45岁,胶质母细胞瘤最常见(47.2%),69.1%接受手术切除,中位无进展生存期9个月,2年总生存率19.7%,H3 K27M突变者总生存更差(P=0.017)。

要点

  • 成人丘脑胶质瘤预后差,2年总生存率仅19.7%,中位无进展生存期9个月。
  • 低级别与高级别丘脑胶质瘤2年生存率分别为31.0%与16.5%。
  • H3 K27M突变与更差总生存相关(P=0.017),作者认为对突变肿瘤可考虑更积极方案。

核心结论

  • 成人丘脑胶质瘤生存预后差,完整手术切除与生存改善相关但并非总能实现,H3 K27M突变与更差生存相关。

研究设计与样本

  • 系统综述,检索PubMed、Scopus和Cochrane数据库,纳入含成人丘脑胶质瘤临床结局数据的文献,共25项研究617例患者。

主要发现

  • 中位年龄45岁(男性58.6%),胶质母细胞瘤最常见(47.2%),82例肿瘤为H3 K27M突变,运动障碍为最常见首发症状(51.8%)。
  • 69.1%的病例接受手术切除,56.3%接受辅助化疗,72.6%接受辅助放疗,15例(2.4%)接受激光间质热疗。
  • 病变侧别(P=0.754)和手术入路(P=0.111)与总生存无显著相关。
  • 中位无进展生存期9个月,总2年生存率19.7%;低级别与高级别丘脑胶质瘤2年生存率分别为31.0%与16.5%。
  • H3 K27M突变胶质瘤总生存更差(P=0.017)。

临床怎么用

  • 作者认为完整手术切除与生存改善相关但不总能实现,H3 K27M突变肿瘤可考虑更积极的治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Thalamic gliomas are rare neoplasms that pose significant surgical challenges. The literature is limited to single-institution retrospective case series. We systematically review the literature and describe the clinical characteristics, treatment strategies, and survival outcomes of adult thalamic gliomas. METHODS: Relevant articles were identified on PubMed, Scopus, and Cochrane databases. Papers containing cases of adult thalamic gliomas with clinical outcome data were included. A comprehensive review of clinical characteristics and survival analysis was conducted. RESULTS: We included 25 studies comprising 617 patients. The median age was 45 years (male = 58.6%). Glioblastoma was the most frequent histological type (47.2%), and 82 tumors were H3 K27M-mutant. Motor deficit was the most common presenting symptom (51.8%). Surgical resection was performed in 69.1% of cases while adjuvant chemotherapy and radiotherapy were administered in 56.3% and 72.6%, respectively. Other treatments included laser interstitial thermal therapy, which was performed in 15 patients (2.4%). The lesion laterality (P = 0.754) and the surgical approach (P = 0.111) did not correlate with overall survival. The median progression-free survival was 9 months, and the overall two-year survival rate was 19.7%. The two-year survival rates of low-grade and high-grade thalamic gliomas were 31.0% and 16.5%, respectively. H3 K27M-mutant gliomas showed worse overall survival (P = 0.017). CONCLUSION: Adult thalamic gliomas are associated with poor survival. Complete surgical resection is associated with improved survival rates but is not always feasible. H3 K27M mutation is associated with worse survival and a more aggressive approach should be considered for mutant neoplasms.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Palmisciano P, El Ahmadieh TY, Haider AS, et al. Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes. J Neurooncol. 2021. PMID: 34797525. doi:10.1007/s11060-021-03898-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。